Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials

@article{Cassese2016EverolimuselutingBV,
  title={Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials},
  author={Salvatore Cassese and Robert A. Byrne and Gjin Ndrepepa and Sebastian Kufner and Adnan Kastrati},
  journal={The Lancet},
  year={2016},
  volume={387},
  pages={537-544}
}
BACKGROUND Bioresorbable coronary stents might improve outcomes of patients treated with percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular scaffold is the most studied of these stent platforms; however, its performance versus everolimus-eluting metallic stents remains poorly defined. We aimed to assess the efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ischaemic heart disease… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 97 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

A randomized trial

  • T Kimura, K Kozuma, K Tanabe
  • olds. J Am Coll Cardiol
  • 2015

Everolimus - eluting bioresorbable vascular scaff olds in patients with coronary artery disease : The ABSORB III trial

  • S Ellis, D Kereiakes, D Metzger
  • N Engl J Med
  • 2015

Randomized comparison of everolimus - eluting Absorb bioresorbable vascular scaff olds vs . everolimus - eluting metallic stents in patients with coronary artery disease : The ABSORB China trial

  • Y Han
  • J Am Coll Cardiol
  • 2015

Similar Papers

Loading similar papers…